Latest Period
Q2 2026
Security Snapshot
NewAmsterdam Pharma Co N.V. - COMMON STOCK (NAMS) Institutional Ownership
CUSIP: N62509109
13F Institutional Holders and Ownership History from Q4 2022 to Q2 2026
Institutions Reporting
194
Shares (Excl. Options)
121,923,180
Price
$33.89
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- NAMS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 121,923,180
- Total 13F value
- $4,129,543,564
- Portfolio coverage rank
- 0.01%
- Share change
- -2,102,122
- Value change
- -$68,479,967
- Number of holders
- 194
- Shares outstanding
- 117,496,170
- SEC-reported price per share
- $27.98
- Insider filing price
- $27.98
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NAMS - NewAmsterdam Pharma Co N.V. - COMMON STOCK is tracked under CUSIP N62509109.
- 194 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 170 to 194 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $3,956,276,151 to $4,129,543,564.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 194 institutions filings for Q2 2026.
Security key
N62509109
Latest holder period
Q2 2026
13F holders
194
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
NAMS full holder history
NewAmsterdam Pharma Co N.V. SEC filings
NewAmsterdam Pharma Co N.V. company facts
NewAmsterdam Pharma Co N.V. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP N62509109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
NAMS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Capital World Investors | 10% | +19% | $460,111,232 | +$89,303,892 | 12,188,377 | +24% | Capital World Investors | 29 May 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $205,220,969 | +$3,481,297 | 11,063,125 | +1.7% | RA Capital Management, L.P. | 31 Mar 2025 |
| FMR LLC | 8.8% | +15% | $382,464,134 | +$58,216,785 | 10,339,663 | +18% | FMR LLC | 30 Jun 2026 |
| Forbion Capital Fund IV Cooperatief U.A. | 8.3% | -12% | $223,140,090 | -$30,222,313 | 9,316,914 | -12% | ForGrowth NAP B.V. | 26 Sep 2025 |
| Frazier Life Sciences X, L.P. | 7.7% | +17% | $245,264,825 | +$36,858,297 | 8,623,939 | +18% | Frazier Life Sciences Public Fund, L.P. | 01 Nov 2025 |
| VIKING GLOBAL INVESTORS LP | 3.7% | -40% | $144,476,598 | -$95,375,616 | 4,203,567 | -40% | VIKING GLOBAL INVESTORS LP | 31 Dec 2025 |
| BCLS II Investco, LP | 1.8% | -59% | $74,671,230 | -$120,221,675 | 2,059,896 | -62% | BCLS Fund III Investments, LP | 12 May 2026 |
As of 30 Jun 2026, 194 institutional investors reported holding 121,923,180 shares of NewAmsterdam Pharma Co N.V. - COMMON STOCK (NAMS). This represents 104% of the company’s total 117,496,170 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
86%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 15% | 18,088,902 | +6.8% | 13% | $613,032,889 |
| Capital World Investors | 10% | 12,230,557 | +10% | 0.05% | $414,493,577 |
| FMR LLC | 8.8% | 10,339,663 | +18% | 0.02% | $350,411,179 |
| RA CAPITAL MANAGEMENT, L.P. | 8.1% | 9,550,191 | 0% | 2.8% | $323,655,973 |
| FCPM III SERVICES B.V. | 7.2% | 8,490,353 | -7.7% | 38% | $287,738,063 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.6% | 4,264,789 | 0% | 1.5% | $144,533,699 |
| VIKING GLOBAL INVESTORS LP | 3.6% | 4,203,567 | 0% | 0.41% | $142,458,886 |
| Bain Capital Life Sciences Investors, LLC | 3.2% | 3,806,566 | -48% | 7.7% | $129,004,522 |
| MAVERICK CAPITAL LTD | 2.8% | 3,267,802 | +49% | 1% | $110,745,810 |
| Duquesne Family Office LLC | 2.6% | 3,070,146 | 0% | 2.4% | $104,047,000 |
| Jupiter Topco LLC | 2.2% | 2,535,682 | 0% | 0.04% | $86,010,334 |
| Medicxi Ventures Management (Jersey) Ltd | 1.9% | 2,208,639 | -17% | 42% | $74,850,776 |
| JENNISON ASSOCIATES LLC | 1.8% | 2,102,286 | -24% | 0.04% | $71,246,471 |
| Orbis Allan Gray Ltd | 1.5% | 1,747,627 | 0.2% | $59,227,079 | |
| Polar Capital Holdings Plc | 1.5% | 1,724,518 | -39% | 0.17% | $58,443,915 |
| Capital International Investors | 1.5% | 1,723,495 | +20% | 0.01% | $58,409,246 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,544,911 | -21% | 0.01% | $52,357,034 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.3% | 1,536,472 | -30% | 0.17% | $52,071,036 |
| Castle Hook Partners LP | 1.2% | 1,371,005 | +31% | 0.5% | $46,463,359 |
| ALLIANCEBERNSTEIN L.P. | 1.1% | 1,259,940 | +5.1% | 0.01% | $40,330,679 |
| AMERIPRISE FINANCIAL INC | 1.1% | 1,253,549 | +66% | 0.01% | $42,482,886 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.99% | 1,167,357 | 0% | $39,562,000 | |
| JPMORGAN CHASE & CO | 0.96% | 1,132,955 | +28% | 0% | $38,373,185 |
| Aberdeen Group plc | 0.94% | 1,102,785 | +32% | 0.05% | $37,373,384 |
| BlackRock, Inc. | 0.91% | 1,063,750 | +20% | 0% | $36,050,487 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Latest
Q2 2026
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 121,923,180 | $4,129,543,564 | -$68,479,967 | $33.89 | 194 |
| 2026 Q1 | 123,556,581 | $3,956,276,151 | +$130,100,007 | $32.01 | 170 |
| 2025 Q4 | 119,332,967 | $4,186,690,487 | -$35,445,065 | $35.08 | 188 |
| 2025 Q3 | 120,390,588 | $3,423,902,136 | +$122,882,388 | $28.44 | 135 |
| 2025 Q2 | 116,368,291 | $2,107,516,504 | +$92,203,105 | $18.11 | 130 |
| 2025 Q1 | 111,177,846 | $2,278,669,708 | +$247,823,372 | $20.47 | 126 |
| 2024 Q4 | 98,611,632 | $2,534,320,573 | +$569,548,998 | $25.70 | 130 |
| 2024 Q3 | 77,090,356 | $1,279,730,929 | +$65,939,934 | $16.60 | 100 |
| 2024 Q2 | 72,010,250 | $1,383,367,935 | -$7,907,090 | $19.21 | 90 |
| 2024 Q1 | 72,152,341 | $1,706,357,479 | +$242,490,357 | $23.65 | 76 |
| 2023 Q4 | 61,897,680 | $691,396,295 | -$81,202 | $11.17 | 32 |
| 2023 Q3 | 50,178,896 | $464,099,871 | +$5,440,463 | $9.25 | 35 |
| 2023 Q2 | 48,833,993 | $580,635,231 | +$184,129,037 | $11.89 | 29 |
| 2023 Q1 | 33,346,896 | $444,858,187 | +$689,119 | $13.26 | 19 |
| 2022 Q4 | 33,516,836 | $362,234,361 | +$362,234,361 | $10.90 | 14 |